Loading stock data…
Arrowhead Pharmaceuticals, Inc. (ARWR)
$86.34-0.15 (-0.17%)
Pre-Market$85.28-1.06 (-1.23%)· Last close Sep 4
Arrowhead Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $86.34 with a market capitalization of $12.2B. Wall Street consensus targets $110.18 (11 analysts), implying a +27.6% move over the next 12 months. The stock is currently near its 52-week high of $95.49, remaining 21.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $73.74M↓ | $264.03M↑ | $256.47M↑ | $27.77M↓ | $542.71M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$141.26M↓ | $40.81M↓ | $44.11M↑ | -$165.55M↓ | $381.20M |
| Net Income | -$132.73M↓ | $30.81M↑ | -$23.75M↑ | -$175.24M↓ | $370.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.73%
Volume
Today's trading volume
757,847
Recent News
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Perry's liquidity event comes as the Arrowhead stock price surged.
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress?
Arrowhead Pharmaceuticals (ARWR) attracted fresh attention after presenting pivotal Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026. The company highlighted triglyceride reductions and fewer acute pancreatitis events in severe hypertriglyceridemia. Arrowhead Pharmaceuticals has seen its share price give back some ground in the past week, with the 1-day share price return down 2.97% and the 7-day share price return down 5%. At the same time, the 90-day share price...
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data